Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Will China’s Life Sciences Industry Evolve?

This article was originally published in PharmAsia News

Executive Summary

Want to know more about how China is changing the global pharma landscape? Participate in our anonymous survey and receive a 15% discount on the PharmAsia Summit-Shanghai Sept. 24-26.

PharmAsia News is pleased to announce the launch of a proprietary survey on the China life sciences industry. We encourage all readers interested in China to participate. The survey should take only five minutes to complete.

As a token of appreciation, all survey participants will receive a 15% discount to attend the PharmAsia Summit-Shanghai (Sept. 24-26, 2012), sponsored by Elsevier Business Intelligence and BayHelix. Survey findings will be released during the Summit as part of an exclusive report on innovation in China.

Goals Of The Survey

The rise of emerging markets like China has provided life sciences companies with significant new growth opportunities, but also the challenge to achieve better health outcomes in regions struggling with affordability barriers and huge unmet medical needs.

China, in particular, is on the radar of most industry executives given its scale. China has risen to become the world’s third largest pharma market, according to data from IMS Health, and some analysts believe China is already the second largest market, trailing only the U.S.

To gain a better understanding of how industry is integrating China into their global strategies, Elsevier is teaming up with BayHelix, an organization of leaders of Chinese heritage in the global life sciences community, and the Monitor Group, a leading strategic consultancy, to launch a proprietary survey of PharmAsia News and Elsevier readers.

Findings from the survey will be included in an exclusive report on innovation in China, to be released during the PharmAsia Summit-Shanghai (Sept. 24-26, 2012). In addition, selected findings will be covered in PharmAsia News during the weeks leading up to the Summit.

Please note that survey participants will remain anonymous. You will be issued a special code at the end of the survey to receive your 15% discount to the PharmAsia Summit-Shanghai.

Thank you for participating!

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel